For years, patients with moderate to severe obstructive sleep apnea who couldn't tolerate CPAP had a second option: an implanted nerve stimulator that kept their airway open during sleep. But roughly 30% of candidates were turned away before the device was ever implanted, because their airway collapsed in a pattern the existing technology couldn't treat.
That changed in March when the FDA granted premarket approval to LivaNova's aura6000 System, the first hypoglossal nerve stimulation (HNS) device cleared in the United States without a contraindication for complete concentric collapse and without requiring a pre-implantation drug-induced sleep endoscopy (DISE) to screen patients out.
The Concentric Collapse Problem
Hypoglossal nerve stimulators work by sending electrical pulses to the nerve that controls tongue and airway muscles, preventing the soft tissue collapse that causes apnea events. The first-generation device on the market, Inspire, targets a specific branch of the hypoglossal nerve and works best when the airway collapses in a front-to-back pattern.
But in patients with complete concentric collapse (CCC), the airway closes circumferentially, like a drawstring bag. Stimulating a single nerve branch can't overcome that pattern, and Inspire's labeling explicitly warns against implanting the device in these patients. Identifying CCC requires DISE, a procedure performed under sedation in which a physician views the airway with an endoscope while the patient sleeps. Patients found to have CCC are sent home without a surgical option.
The clinical impact of this exclusion is significant. Studies estimate that approximately 30% of sleep apnea patients evaluated for HNS have concentric collapse patterns, effectively disqualifying them from the only implantable treatment available until now.
A Different Engineering Approach
The aura6000 takes a fundamentally different approach. Rather than targeting a distal nerve branch, the device places six electrodes on the proximal trunk of the hypoglossal nerve, closer to where it exits the brainstem. This position gives the system access to a broader set of the muscles controlling airway patency.
LivaNova's PolySync algorithm uses the six electrodes to deliver customized stimulation patterns, adjusting which combination of electrodes fire and at what intensity. The idea is that by accessing the nerve trunk rather than a single branch, the device can recruit enough muscle groups to counteract even circumferential collapse.
The design trade-off is surgical: placing electrodes on the proximal nerve trunk requires a different implantation technique than existing devices, and the procedure involves positioning the six-contact cuff electrode precisely around the nerve. But the advantage is that clinicians can titrate stimulation across electrode combinations post-operatively, fine-tuning therapy without additional surgery.
OSPREY Trial Results
The FDA approval is based on data from the OSPREY pivotal trial, a multi-center, randomized controlled study that deliberately did not exclude patients with concentric collapse. A predictor algorithm estimated that approximately 30% of participants were at high risk for CCC, making the trial population representative of the broader sleep apnea patient base that HNS devices are intended to serve.
At 12 months, the results showed:
- 65% responder rate (defined as at least 50% AHI reduction and AHI below 20)
- Median AHI dropped from 34.3 to 11.0 events per hour
- A 66% reduction in AHI and 63% decrease in oxygen desaturation index at 6 months, sustained through 13 months
The trial met both its primary safety and efficacy endpoints. Adverse events were consistent with those seen in other HNS device trials, with no unexpected safety signals.
What's Coming Next
LivaNova plans to launch the aura6000 commercially in the first half of 2027, following the additional manufacturing and training steps required before implantation centers can begin offering the device. The company has also indicated that a next-generation version with MRI compatibility and a 15-year rechargeable battery is in development.
The current device is not MRI-compatible, which is a limitation shared with some cardiac implants and other neurostimulation devices. For patients who require frequent MRI imaging, this may factor into the treatment decision. The Genio system from Nyxoah, another HNS device that received FDA approval, does offer MRI compatibility but uses a different stimulation approach.
What This Means for Patients
For the estimated 30% of sleep apnea patients with concentric collapse who were previously told they weren't candidates for an implanted nerve stimulator, the aura6000 represents the first device designed and tested specifically to include them. The elimination of the mandatory DISE screening also simplifies the evaluation pathway, removing a step that added cost, time, and a sedation procedure before patients could even learn whether they qualified.
Patients interested in the aura6000 should be aware that the device will not be available at implantation centers until 2027. In the interim, other treatment options for those who cannot tolerate CPAP include oral appliances, positional therapy, the oral medication landscape that is rapidly evolving, and existing HNS devices for patients without concentric collapse.
The broader significance is competitive: three distinct HNS devices are now FDA-approved in the United States (Inspire, Genio, and aura6000), each with different engineering approaches, implantation techniques, and patient eligibility criteria. That competition is likely to drive continued innovation and, over time, make implantable therapy accessible to a wider range of sleep apnea patients.
